Codexis, Inc. (CDXS)

NasdaqGS • Currently up 0.06 (+5.88%) in today's trading session

1 member of Congress has disclosed 2 trades in Codexis, Inc. (CDXS) via STOCK Act filings. The most recent disclosure was a purchase by Lamar Smith on 6 April 2018. Aggregate disclosed activity totals roughly $16K in purchases (midpoint estimates from bracketed disclosure amounts).

Codexis, Inc. is currently trading at $1.08, positioned at 6% of its 52-week range ($0.96 – $2.98).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$1.08
24h Change
+0.06 (+5.88%)
52 Week Range
$0.96–$2.98
View on NASDAQ

Codexis, Inc. Price History and Technical Analysis

Congressional Trading Activity for CDXS

Select to highlight on chart
2 transactions
Compliance: 50%
Lamar Smith6 Apr 20188 May 2018PurchaseStock$1,001 - $15,000N/A
Lamar Smith6 Apr 20183 May 2019PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$118.27M

Volume

400.32K

Beta

2.39

P/E Ratio

-3.18

Fundamentals

EPS

$-0.34

Div. Yield

-

Open

$1.03

Day Range

$1.02 – $1.10

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Alison Moore
IPO Date
2010-04-22

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemi...

Earnings

Next Report

Q3 2026

12 Nov

EPS Est.

$-0.10

Rev. Est.

$18.7M

Days Until

3

Recent Quarters

Q2 202611 Aug
EPS$-0.13
Beat 8.2%
Q1 20267 May
EPS$-0.10
Beat 9.1%
Q4 202511 Mar
EPS$0.11
Beat 1000.0%
Q3 20256 Nov
EPS$-0.22
Miss 46.7%
Q2 202513 Aug
EPS$-0.16
Beat 5.9%
Q1 202514 May
EPS$-0.25
Miss 25.0%
Q4 202427 Feb
EPS$-0.13
Miss 225.0%
Q3 202431 Oct
EPS$-0.29
Miss 16.0%
Q2 20248 Aug
EPS$-0.32
Miss 23.1%
Q1 20242 May
EPS$-0.16
Beat 5.9%
Q4 202328 Feb
EPS$0.02
Beat 112.5%
Q3 20232 Nov
EPS$-0.50
Miss 56.3%
Q2 20233 Aug
EPS$-0.17
Beat 19.1%
Q1 20234 May
EPS$-0.34
Miss 17.2%
Q4 202223 Feb
EPS$-0.19
Beat 17.4%
Q3 20223 Nov
EPS$-0.15
Beat 16.7%
Q2 20224 Aug
EPS$-0.04
Beat 71.4%
Q1 20225 May
EPS$-0.13
Beat 27.8%
Q4 202124 Feb
EPS$-0.16
Beat 11.1%
Q3 20214 Nov
EPS$0.03
Beat 133.3%
Q2 20215 Aug
EPS$-0.07
Beat 58.8%
Q1 20216 May
EPS$-0.14
Beat 30.0%
Q4 202025 Feb
EPS$-0.06
Beat 53.9%
Q3 20205 Nov
EPS$-0.10
Beat 37.5%
Q2 20206 Aug
EPS$-0.11
Beat 56.0%
Q1 20207 May
EPS$-0.09
Beat 30.8%
Q4 201927 Feb
EPS$0.02
Miss 66.7%
Q3 20195 Nov
EPS$0.04
Beat 150.0%
Q2 20196 Aug
EPS$-0.08
Miss 24.1%
Q1 20196 May
EPS$-0.05
Beat 16.7%
Q4 201826 Feb
EPS$0.03
Beat 70.5%
Q3 20188 Nov
EPS$-0.04
Beat 42.9%
Q2 20188 Aug
EPS$-0.02
Beat 83.3%
Q1 201810 May
EPS$-0.05
Beat 28.6%
Q4 20178 Mar
EPS$0.02
Miss 60.0%
Q3 20179 Nov
EPS$-0.21
Miss 31.3%
Q2 20179 Aug
EPS$-0.13
Beat 0.0%
Q1 20179 May
EPS$-0.18
Miss 20.0%
Q4 20169 Mar
EPS$-0.13
Miss 18.2%
Q3 20168 Nov
EPS$0.03
Beat 121.4%
Q2 20169 Aug
EPS$0.05
Beat 53.9%
Q1 20169 May
EPS$-0.17
Miss 13.3%
Q4 20153 Mar
EPS$-0.05
Beat 0.0%
Q3 20154 Nov
EPS$0.13
Beat 218.2%
Q2 201511 Aug
EPS$-0.14
Beat 0.0%
Q1 20157 May
EPS$-0.14
Miss 7.7%
Q4 20143 Mar
EPS$0.01
Beat 100.0%
Q3 20144 Nov
EPS$-0.05
Beat 16.7%
Q2 20146 Aug
EPS$-0.22
Miss 46.7%
Q1 20147 May
EPS$-0.17
Miss 70.0%
Q4 201311 Mar
EPS$-0.26
Miss 23.8%
Q3 201312 Nov
EPS$-0.24
Beat 20.0%
Q2 20139 Aug
EPS$-0.33
Miss 17.9%
Q1 20137 May
EPS$-0.25
Beat 26.5%
Q4 201227 Feb
EPS$-0.41
Miss 32.3%
Q3 20127 Nov
EPS$-0.06
Beat 62.5%
Q2 20129 Aug
EPS$-0.15
Beat 21.1%
Q1 201210 May
EPS$-0.21
Miss 23.5%
Q4 20117 Feb
EPS$-0.15
Miss 36.4%
Q3 20111 Nov
EPS$-0.08
Beat 0.0%
Q2 201128 Jul
EPS$-0.14
Miss 55.6%
Q1 20115 May
EPS$-0.10
Miss 42.9%
Q4 20103 Feb
EPS$-0.01
Beat 76.5%
Q3 201028 Oct
EPS$-0.08
Beat 38.5%
Q2 20105 Aug
EPS$-0.15
Miss 7.1%
Q3 200931 Dec
EPS$-1.97
Q2 200930 Sept
EPS$-2.35
Q1 200930 Jun
EPS$-1.09
Q4 200831 Mar
EPS$-2.35
Q3 200831 Dec
EPS$-2.44
Q4 200731 Mar
EPS$-5.12
Q4 200631 Mar
EPS$-1.88

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

WST

West Pharmaceutical Services, Inc.

47
$399.81+7.33 (+1.87%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

UNH

UnitedHealth Group Incorporated

47
$394.15-1.57 (-0.40%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

GOOGL

Alphabet Inc.

17
$284.78+2.21 (+0.78%)
Communication Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about CDXS

Which members of Congress have traded CDXS?
1 member of Congress has disclosed 2 trade in Codexis, Inc. (CDXS) under the STOCK Act: Lamar Smith.
When was CDXS most recently disclosed by Congress?
The most recent CDXS disclosure was a purchase by Lamar Smith on 6 April 2018.
What is the total disclosed congressional trading volume for CDXS?
Members of Congress have disclosed approximately $16K in CDXS purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in CDXS?
This CDXS page updates as soon as new STOCK Act disclosures are filed for Codexis, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.